Publikationen in Zusammenarbeit mit Forschern von Fundación Jiménez Díaz (30)

2024

  1. Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort

    Clinical Kidney Journal, Vol. 17, Núm. 8

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

  3. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)

    Clinical Kidney Journal, Vol. 16, Núm. 9, pp. 1384-1402

2022

  1. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  2. Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 6, pp. 1137-1153

  3. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 32, Núm. 2

  2. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Kidney International Reports, Vol. 6, Núm. 9, pp. 2392-2403

  3. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  4. The authors reply

    Kidney International

  5. The authors reply

    Kidney International

  6. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 6, pp. 1002-1009

  2. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

  3. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. Glomerular hematuria: Cause or consequence of renal inflammation?

    International Journal of Molecular Sciences, Vol. 20, Núm. 9

  2. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

    Kidney International, Vol. 96, Núm. 4, pp. 995-1004

2017

  1. Eculizumab in secondary atypical haemolytic uraemic syndrome

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 466-474

2016

  1. Efectos pleiotrópicos del paricalcitol, más allá del metabolismo óseo-mineral

    Nefrologia